{
  "topic_name": "信心倍增，一线优选(1G TKI偏好)",
  "topic_id": "XBL-1G_TOPIC_20260224_001",
  "topic_describe": "信心倍增，一线优选(1G TKI偏好)",
  "topic_mcc_code": "ASC0061504-125597",
  "home_page_url": "pages/page1/index.html",
  "home_page_union_id": "XBL-1G_PAGE_20260224_001.01.01",
  "chapter_num": 7,
  "pages_num": 11,
  "chapter_info": [
    {
      "chapter_id": "XBL-1G_CHAPTER_20260224_001.01",
      "chapter_no": 1,
      "chapter_title": "CML治疗挑战(1G TKI偏好)",
      "chapter_subtitle": "CML治疗挑战(1G TKI偏好)",
      "chapter_pages_num": 1,
      "chapter_page_home_page_url": "pages/page1/index.html",
      "chapter_page_union_id": "XBL-1G_PAGE_20260224_001.01.01",
      "pages_info": [{
        "page_union_id": "XBL-1G_PAGE_20260224_001.01.01",
        "page_no": 1,
        "page_name": "CML治疗进阶：从优化生存到通往治愈，仍有三大治疗挑战",
        "page_describe": "开启STAMP药物时代，奔赴CML治愈希望",
        "page_path": "pages\\page1\\index.html",
        "page_url": "pages/page1/index.html",
        "page_mcc_code": "",
        "page_chapter_number": 1,
        "page_chapter_title": "CML治疗挑战(1G TKI偏好)",
        "page_chapter_subtitle": "CML治疗挑战(1G TKI偏好)",
        "page_key_message": "CML治疗进阶：从优化生存到通往治愈，仍有三大治疗挑战"
      }]
    },
    {
      "chapter_id": "XBL-1G_CHAPTER_20260224_001.02",
      "chapter_no": 2,
      "chapter_title": "信倍立核心优势(1G TKI偏好)",
      "chapter_subtitle": "信倍立核心优势(1G TKI偏好)",
      "chapter_pages_num": 2,
      "chapter_page_home_page_url": "pages/page2/index.html",
      "chapter_page_union_id": "XBL-1G_PAGE_20260224_001.02.01",
      "pages_info": [{
        "page_union_id": "XBL-1G_PAGE_20260224_001.02.01",
        "page_no": 1,
        "page_name": "ASC4FIRST研究：首个且唯一头对头比较信倍立(阿思尼布) vs. 传统TKIs用于新诊断CML的III期临床研究",
        "page_describe": "ASC4FIRST研究",
        "page_path": "pages\\page2\\index.html",
        "page_url": "pages/page2/index.html",
        "page_mcc_code": "",
        "page_chapter_number": 2,
        "page_chapter_title": "信倍立核心优势(1G TKI偏好)",
        "page_chapter_subtitle": "信倍立核心优势(1G TKI偏好)",
        "page_key_message": "ASC4FIRST研究：首个且唯一头对头比较信倍立(阿思尼布) vs. 传统TKIs用于新诊断CML的III期临床研究"
      },{
        "page_union_id": "XBL-1G_PAGE_20260224_001.02.02",
        "page_no": 2,
        "page_name": "ASC4FIRST研究证实信倍立(阿思尼布)较传统TKIs：双倍深度缓解；减半AE停药；双倍提升QoL",
        "page_describe": "ASC4FIRST研究证实信倍立(阿思尼布)较传统TKIs：双倍深度缓解；减半AE停药；双倍提升QoL",
        "page_path": "pages\\page2\\index2.html",
        "page_url": "pages/page2/index2.html",
        "page_mcc_code": "",
        "page_chapter_number": 2,
        "page_chapter_title": "信倍立核心优势(1G TKI偏好)",
        "page_chapter_subtitle": "信倍立核心优势(1G TKI偏好)",
        "page_key_message": "ASC4FIRST研究证实信倍立(阿思尼布)较传统TKIs：双倍深度缓解；减半AE停药；双倍提升QoL"
      }]
    },
    {
      "chapter_id": "XBL-1G_CHAPTER_20260224_001.03",
      "chapter_no": 3,
      "chapter_title": "不耐受患者：长久治安(1G TKI偏好)",
      "chapter_subtitle": "不耐受患者：长久治安(1G TKI偏好)",
      "chapter_pages_num": 2,
      "chapter_page_home_page_url": "pages/page3/index.html",
      "chapter_page_union_id": "XBL-1G_PAGE_20260224_001.03.01",
      "pages_info": [{
        "page_union_id": "XBL-1G_PAGE_20260224_001.03.01",
        "page_no": 1,
        "page_name": "CSH 2025推荐：患者管理的重点在于预防和(或)减轻毒性反应，同时提高生活质量",
        "page_describe": "CSH 2025推荐：患者管理的重点在于预防和(或)减轻毒性反应，同时提高生活质量",
        "page_path": "pages\\page3\\index.html",
        "page_url": "pages/page3/index.html",
        "page_mcc_code": "",
        "page_chapter_number": 3,
        "page_chapter_title": "不耐受患者：长久治安(1G TKI偏好)",
        "page_chapter_subtitle": "不耐受患者：长久治安(1G TKI偏好)",
        "page_key_message": "CSH 2025推荐：患者管理的重点在于预防和(或)减轻毒性反应，同时提高生活质量"
      },{
        "page_union_id": "XBL-1G_PAGE_20260224_001.03.02",
        "page_no": 2,
        "page_name": "信倍立(阿思尼布)AE更少、毒性更低、QOL更高，让更多患者可以”舒服”地追求更高的治疗目标",
        "page_describe": "信倍立(阿思尼布)AE更少、毒性更低、QOL更高，让更多患者可以”舒服”地追求更高的治疗目标",
        "page_path": "pages\\page3\\index2.html",
        "page_url": "pages/page3/index2.html",
        "page_mcc_code": "",
        "page_chapter_number": 3,
        "page_chapter_title": "不耐受患者：长久治安(1G TKI偏好)",
        "page_chapter_subtitle": "不耐受患者：长久治安(1G TKI偏好)",
        "page_key_message": "信倍立(阿思尼布)AE更少、毒性更低、QOL更高，让更多患者可以”舒服”地追求更高的治疗目标"
      }]
      },
    {
      "chapter_id": "XBL-1G_CHAPTER_20260224_001.04",
      "chapter_no": 4,
      "chapter_title": "高危患者：阻止进展(1G TKI偏好)",
      "chapter_subtitle": "高危患者：阻止进展(1G TKI偏好)",
      "chapter_pages_num": 2,
      "chapter_page_home_page_url": "pages/page4/index.html",
      "chapter_page_union_id": "XBL-1G_PAGE_20260224_001.04.01",
      "pages_info": [{
        "page_union_id": "XBL-1G_PAGE_20260224_001.04.01",
        "page_no": 1,
        "page_name": "CSH 2025：CML治疗目标包含减少疾病进展使CML患者寿命正常化",
        "page_describe": "CSH 2025：CML治疗目标包含减少疾病进展使CML患者寿命正常化",
        "page_path": "pages\\page4\\index.html",
        "page_url": "pages/page4/index.html",
        "page_mcc_code": "",
        "page_chapter_number": 4,
        "page_chapter_title": "高危患者：阻止进展(1G TKI偏好)",
        "page_chapter_subtitle": "高危患者：阻止进展(1G TKI偏好)",
        "page_key_message": "CSH 2025：CML治疗目标包含减少疾病进展使CML患者寿命正常化"
      },{
        "page_union_id": "XBL-1G_PAGE_20260224_001.04.02",
        "page_no": 2,
        "page_name": "信倍立(阿思尼布)更快更高达到最佳治疗反应，EFS更优，减少疾病进展；守护所有患者，包括高风险人群，改善预后",
        "page_describe": "信倍立(阿思尼布)更快更高达到最佳治疗反应，EFS更优，减少疾病进展；守护所有患者，包括高风险人群，改善预后",
        "page_path": "pages\\page4\\index2.html",
        "page_url": "pages/page4/index2.html",
        "page_mcc_code": "",
        "page_chapter_number": 4,
        "page_chapter_title": "高危患者：阻止进展(1G TKI偏好)",
        "page_chapter_subtitle": "高危患者：阻止进展(1G TKI偏好)",
        "page_key_message": "信倍立(阿思尼布)更快更高达到最佳治疗反应，EFS更优，减少疾病进展；守护所有患者，包括高风险人群，改善预后"
      }]
      },
    {
      "chapter_id": "XBL-1G_CHAPTER_20260224_001.05",
      "chapter_no": 5,
      "chapter_title": "年轻、低/中危患者：奔赴TFR(1G TKI偏好)",
      "chapter_subtitle": "年轻、低/中危患者：奔赴TFR(1G TKI偏好)",
      "chapter_pages_num": 2,
      "chapter_page_home_page_url": "pages/page5/index.html",
      "chapter_page_union_id": "XBL-1G_PAGE_20260224_001.05.01",
      "pages_info": [{
        "page_union_id": "XBL-1G_PAGE_20260224_001.05.01",
        "page_no": 1,
        "page_name": "ELN 2025、CSCO 2025推荐：低/中危、年轻患者、计划妊娠患者有望追求TFR",
        "page_describe": "ELN 2025、CSCO 2025推荐：低/中危、年轻患者、计划妊娠患者有望追求TFR",
        "page_path": "pages\\page5\\index.html",
        "page_url": "pages/page5/index.html",
        "page_mcc_code": "",
        "page_chapter_number": 5,
        "page_chapter_title": "年轻、低/中危患者：奔赴TFR(1G TKI偏好)",
        "page_chapter_subtitle": "年轻、低/中危患者：奔赴TFR(1G TKI偏好)",
        "page_key_message": "ELN 2025、CSCO 2025推荐：低/中危、年轻患者、计划妊娠患者有望追求TFR"
      },{
        "page_union_id": "XBL-1G_PAGE_20260224_001.05.02",
        "page_no": 2,
        "page_name": "信倍立(阿思尼布)更早更深更持续的分子学缓解，对T细胞的抑制小，提高患者TFR可及性及成功率",
        "page_describe": "信倍立(阿思尼布)更早更深更持续的分子学缓解，对T细胞的抑制小，提高患者TFR可及性及成功率",
        "page_path": "pages\\page5\\index2.html",
        "page_url": "pages/page5/index2.html",
        "page_mcc_code": "",
        "page_chapter_number": 5,
        "page_chapter_title": "年轻、低/中危患者：奔赴TFR(1G TKI偏好)",
        "page_chapter_subtitle": "年轻、低/中危患者：奔赴TFR(1G TKI偏好)",
        "page_key_message": "信倍立(阿思尼布)更早更深更持续的分子学缓解，对T细胞的抑制小，提高患者TFR可及性及成功率"
      }]
      },
    {
      "chapter_id": "XBL-1G_CHAPTER_20260224_001.06",
      "chapter_no": 6,
      "chapter_title": "权威指南推荐，全人群获益(1G TKI偏好)",
      "chapter_subtitle": "权威指南推荐，全人群获益(1G TKI偏好)",
      "chapter_pages_num": 1,
      "chapter_page_home_page_url": "pages/page6/index.html",
      "chapter_page_union_id": "XBL-1G_PAGE_20260224_001.06.01",
      "pages_info": [{
        "page_union_id": "XBL-1G_PAGE_20260224_001.06.01",
        "page_no": 1,
        "page_name": "信倍立(阿思尼布)权威指南一线推荐，全人群获益",
        "page_describe": "信倍立(阿思尼布)权威指南一线推荐，全人群获益",
        "page_path": "pages\\page6\\index.html",
        "page_url": "pages/page6/index.html",
        "page_mcc_code": "",
        "page_chapter_number": 6,
        "page_chapter_title": "权威指南推荐，全人群获益(1G TKI偏好)",
        "page_chapter_subtitle": "权威指南推荐，全人群获益(1G TKI偏好)",
        "page_key_message": "信倍立(阿思尼布)权威指南一线推荐，全人群获益"
      }]
      },
    {
      "chapter_id": "XBL-1G_CHAPTER_20260224_001.07",
      "chapter_no": 7,
      "chapter_title": "STAMP机制和耐药(1G TKI偏好)",
      "chapter_subtitle": "STAMP机制和耐药(1G TKI偏好)",
      "chapter_pages_num": 1,
      "chapter_page_home_page_url": "pages/page7/index.html",
      "chapter_page_union_id": "XBL-1G_PAGE_20260224_001.07.01",
      "pages_info": [{
        "page_union_id": "XBL-1G_PAGE_20260224_001.07.01",
        "page_no": 1,
        "page_name": "信倍立(阿思尼布)是全球首个且唯一的STAMP治疗药物",
        "page_describe": "信倍立(阿思尼布)是全球首个且唯一的STAMP治疗药物",
        "page_path": "pages\\page7\\index.html",
        "page_url": "pages/page7/index.html",
        "page_mcc_code": "",
        "page_chapter_number": 7,
        "page_chapter_title": "STAMP机制和耐药(1G TKI偏好)",
        "page_chapter_subtitle": "STAMP机制和耐药(1G TKI偏好)",
        "page_key_message": "信倍立(阿思尼布)是全球首个且唯一的STAMP治疗药物"
      }]
    }
  ]
}